Thiazolidinediones with high glucose-lowering efficacy reduce secondary CV endpoints; ADA and EASD’s consensus
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok